BEAUTYFARM MED (02373) continued its ascent, rising over 6%. At the time of writing, the stock was up 6.04%, trading at HKD 28.46, with a turnover of HKD 9.5031 million. Recently, BEAUTYFARM MED issued a positive profit alert for 2025. The company anticipates 2025 revenue to be no less than RMB 3 billion, representing a year-on-year increase of no less than 16%; adjusted net profit is expected to be no less than RMB 380 million, a surge of no less than 40% year-on-year; net profit is projected to be no less than RMB 340 million, growing by no less than 34% year-on-year. The board attributes the performance improvement primarily to accelerated expansion through acquisitions and robust organic growth momentum. The company highlighted that with the full integration of Nairui'er into the BEAUTYFARM brand portfolio, the group's business footprint has rapidly penetrated core cities in the Greater Bay Area and surrounding key regions, leading to a significant increase in market share. Post-acquisition integration synergies continue to be realized; in the first half of 2025, Nairui'er's adjusted net profit margin dramatically increased to 10.4%, up from 6.5% prior to the acquisition. Furthermore, leveraging the competitive advantages of its unique business model, the group has continuously upgraded its medical service capabilities, resulting in a steady increase in the revenue contribution from high-margin medical services during 2025. Coupled with ongoing enhancements to its refined operational systems, the group's net profit margin has been climbing steadily.